Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 1;1(1):157-163.
doi: 10.1089/imr.2022.0070. Epub 2022 Aug 26.

Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study

Joji Suzuki  1   2 , Bianca Martin  1 , Sara Prostko  1 , Peter R Chai  2   3   4   5   6 , Roger D Weiss  2   7
Affiliations

Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study

Joji Suzuki et al. Integr Med Rep. .

Abstract

Background: Opioid use disorder (OUD) remains a major public health concern. Despite the use of medications for OUD such as buprenorphine, the current gold-standard treatment, relapse in the context of increased craving remains common. Cannabidiol (CBD) has been shown to reduce cue-induced craving in individuals with OUD, but among those who were not receiving any buprenorphine treatment. This small proof-of-concept open-label study sought to evaluate the effect of CBD on cue-induced craving among individuals with OUD who were being actively treated with buprenorphine.

Methods: Participants (n = 5) received CBD (Epidiolex®) 600 mg once daily for 3 consecutive days in an open-label manner. Primary outcome was cue-induced craving measured on a visual analog scale of 0 to 10, calculated as the difference in craving in response to drug-related versus neutral cues. The cue-reactivity paradigm was performed at baseline before CBD administration, and was repeated after 3 days of CBD. Secondary outcomes included scores on depression, anxiety, pain, opioid withdrawal, and side effects.

Results: All participants were actively taking buprenorphine for an average of 37.8 months (range 1-120 months). Cue-induced craving was significantly lower after CBD dosing compared with baseline (0.4 vs. 3.2, paired t-test, p = 0.0046). No significant changes in scores for depression, anxiety, pain, or opioid withdrawal were noted. CBD was well tolerated, although one participant experienced moderate sedation; otherwise, no other adverse effects were reported.

Conclusions: Given the high risk for bias in a small uncontrolled open label study such as this, results must be interpreted with caution. A larger adequately powered trial with a suitable control group is needed to confirm the finding that CBD may help to reduce cue-induced craving among individuals with OUD currently on buprenorphine treatment. Research should further evaluate whether adjunctive use of CBD can improve clinical outcomes for individuals with OUD maintained on buprenorphine. ClinicalTrials.gov (NCT04192370).

Keywords: buprenorphine; cannabidiol; cue-induced craving; opioid use disorder.

PubMed Disclaimer

Conflict of interest statement

Dr. Weiss has consulted to Analgesic Solutions, Wayland, MA, ACI Clinical, Bala Cynwyd, PA, and Alkermes, Inc., Waltham, MA. All other authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mattson CL. Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. MMWR Morb Mortal Wkly Rep 2021;70(6):202–207; doi: 10.15585/mmwr.mm7006a4. - DOI - PMC - PubMed
    1. CDC. Save Lives Now. 2021. Available from: https://www.cdc.gov/drugoverdose/pubs/featured-topics/save-lives-now.html [Last accessed: June 18, 2021].
    1. Centers for Disease Control and Prevention. Evidence-Based Strategies for Preventing Opioid Overdoses: What's Working in the United States. Atlanta, GA: National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2018.
    1. Fullerton CA, Kim M, Thomas CP, et al. . Medication-assisted treatment with methadone: Assessing the evidence. Psychiatr Serv 2014;65(2):146–157; doi: 10.1176/appi.ps.201300235. - DOI - PubMed
    1. Mattick RP, Breen C, Kimber J, et al. . Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014;2(2):CD002207; doi: 10.1002/14651858.CD002207.pub4. - DOI - PMC - PubMed

Associated data

LinkOut - more resources